Answers are grounded in this paper and cite their sources.
Introduction. Multi-cycle assessment of abbreviated new drug applications (ANDAs) delays generic-medicine availability. GDUFA III (effective FY2023) introduced assessment enhancements intended to reduce the number of cycles. Whether this objective is yet observable in published performance data has not been examined. Methods. From public FDA Generic Drugs Program Activities Reports, a fiscal-year series spanning GDUFA II (FY2018–FY2022) and GDUFA III (FY2023–FY2025) was assembled, the first public longitudinal GDUFA II-to-III comparison of first-cycle performance. The first-cycle approval rate proxied assessment-cycle efficiency, with complete-response volume, a workload-adjusted measure, and approval times as secondary measures. Results. The first-cycle approval rate stayed within a narrow band (15.7%–19.9%; era means near 17.3% and 18.8%), within ordinary year-to-year variation, with no discontinuity at FY2023, and single-year endpoints partly denominator-driven. An illustrative power analysis indicates the observed 1.5-point difference would need roughly nine to twenty further years to detect, whereas a three-point shift would show within about two years, so three years cannot yet evaluate the goal. The workload-adjusted burden declined gradually, beginning before GDUFA III; approval times were non-monotonic; manufacturing and drug-product deficiencies predominated. Discussion. The cycle-minimization objective is not yet detectable as a structural change, and the modest improvement present continues a trend already under way before GDUFA III. Conclusion. The reported deficiency composition locates the predominant drivers in submission quality fixed at dossier preparation; whether this delay is preventable upstream remains a hypothesis for application-level testing. Durable cycle reduction may require dossier improvement alongside review-stage reform.
No takes yet. Share an insight, caveat, or question.
Sumiya Mushtaq (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: